0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LY75

LY75

Brief Information

Name:Lymphocyte antigen 75
Target Synonym:LY75,CD205,Lymphocyte Antigen 75,C-Type Lectin Domain Family 13 Member B,CLEC13B,DEC-205,CD205 Antigen,Gp200-MR6,Ly-75
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
LY5-H52H3 Human Human LY75 / CD205 Protein, His Tag
LY5-H52H3-structure
LY5-H52H3-sds
LY5-M52H5 Mouse Mouse LY75 / CD205 Protein, His Tag (MALS verified)
LY5-M52H5-structure
LY5-M52H5-sds

Part of Bioactivity data

LY5-M52H5-ELISA
Mouse LY75, His Tag (Cat. No. ) MALS images

The purity of Mouse LY75, His Tag (Cat. No. LY5-M52H5) was more than 90% and the molecular weight of this protein is around 235-255 kDa verified by SEC-MALS.

  • Background
    lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Synonym Name

LY75,CD205,DEC-205,CLEC13B,Lymphocyte antigen 75,gp200-MR6

Background

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Rasdegafusp alfa CDX-1401 Phase 2 Clinical Ludwig Institute For Cancer Research Ovarian Neoplasms; Carcinoma, Transitional Cell; Mesothelioma; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
MEN-1309 MEN-1309; OBT-076 Phase 1 Clinical Oxford Biotherapeutics, Menarini Solid tumours; Breast Neoplasms; Lymphoma, Non-Hodgkin Details

This web search service is supported by Google Inc.

totop